Your browser doesn't support javascript.
loading
EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer after PARP Inhibition Progression.
Lheureux, Stephanie; Oaknin, Ana; Garg, Swati; Bruce, Jeffrey P; Madariaga, Ainhoa; Dhani, Neesha C; Bowering, Valerie; White, Justin; Accardi, Sarah; Tan, Qian; Braunstein, Marsela; Karakasis, Katherine; Cirlan, Iulia; Pedersen, Stephanie; Li, Tiantiam; Fariñas-Madrid, Lorena; Lee, Yeh Chen; Liu, Zhihui Amy; Pugh, Trevor J; Oza, Amit M.
Afiliação
  • Lheureux S; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
  • Oaknin A; Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
  • Garg S; Department of Medical Oncology, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Bruce JP; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
  • Madariaga A; Princess Margaret Genomics Centre, University Health Network, Toronto, Ontario, Canada.
  • Dhani NC; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
  • Bowering V; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
  • White J; Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
  • Accardi S; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
  • Tan Q; Ozmosis Research Inc., Toronto, Ontario, Canada.
  • Braunstein M; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
  • Karakasis K; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
  • Cirlan I; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
  • Pedersen S; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
  • Li T; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
  • Fariñas-Madrid L; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
  • Lee YC; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
  • Liu ZA; Department of Medical Oncology, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Pugh TJ; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
  • Oza AM; Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.
Clin Cancer Res ; 26(16): 4206-4215, 2020 08 15.
Article em En | MEDLINE | ID: mdl-32444417
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Ftalazinas / Piperazinas / Quinazolinas / Poli(ADP-Ribose) Polimerases Tipo de estudo: Clinical_trials Limite: Aged / Female / Humans / Middle aged Idioma: En Revista: Clin Cancer Res Assunto da revista: NEOPLASIAS Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Canadá
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Ftalazinas / Piperazinas / Quinazolinas / Poli(ADP-Ribose) Polimerases Tipo de estudo: Clinical_trials Limite: Aged / Female / Humans / Middle aged Idioma: En Revista: Clin Cancer Res Assunto da revista: NEOPLASIAS Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Canadá